Objective To investigate the effect of up-regulation of long-chain non-coding RNA GHET1 on the prognosis of liver transplantation patients with hepatocellular carcinoma, and to explore whether it can be used as a potential molecular target for the detection and treatment of liver transplantation for liver cancer. Methods Twenty samples of hepatocellular carcinoma and corresponding cancer adjacent tissues were collected. The samples of hepatocellular carcinoma from 106 patients who underwent orthotopic liver transplantation were collected. Theywere divided into recurrence group and non-recurrence group according to whether there was a recurrence of hepatic carcinoma. According to the expression of GHET1, they were divided into the high expression group and low expression group. Quantitative real-time PCR （qRT-PCR） was used to detect the expression of GHET1 in all tissues. The relationships between GHET1 expression, the clinicopathological features and prognosis of HCC were analyzed. Results Compared with the adjacent non-tumor tissues, the expression of GHET1 was increased in hepatocellular carcinoma（P ＜ 0.001）. The results of clinical pathology analysis showed that GHET1 expression was closely related with tumor capsule （P ＜ 0.001）， tumor diameter （P ＜ 0.01）， differentiation grade （P ＜ 0.01）， vascular invasion（P ＜ 0.01） and TNM stage（P ＜ 0.01），but not related to the patient's age， gender， cirrhosis， serum AFP levels， serum NLR values， tumor location and tumor number （P ＞ 0.05）. In 106 liver cancer patients who underwent liver transplantation, the expressions of GHET1 were significantly higher in the recurrence group compared to the non-recurrence group （P ＜ 0.001） and the low-expression group. The cumulative recurrence rate in the high-expression group was significantly higher （P ＜ 0.05）. The cumulative survival rate in the high-expression group was significantly lower （P ＜ 0.001）. The difference was statistically significant. Conclusion GHET1 overexpression is associated with clinicopathological feature and poor prognosis. This conclusion suggests that GHET1 may be involved in the occurrence and development of HCC, and it can be used as a prognostic marker and clinical target in liver cancer patients who undergo liver transplantation.

目的 探讨长链非编码 RNA GHET1 对肝癌肝移植患者预后的影响，探讨其可否作为检测和 治疗肝癌肝移植的潜在分子靶标。方法 收集 20 例肝癌组织及其对应的癌旁组织。另外收集 106 例肝癌 肝移植患者的组织，根据是否复发肝癌分为复发组与未复发组，根据 GHET1 表达分为高表达组与低表达 组。采用实时荧光定量 PCR（qRT-PCR）检测所有组织的 GHET1 表达，结合临床资料分析 GHET1 表达 与肝癌肝移植临床病理特征和预后的关系。结果 与邻近正常组织相比，GHET1 在肝癌组织中表达增高 （P ＜ 0.001），临床病理学特征分析结果表明 GHET1 表达与肿瘤包膜（P ＜ 0.001）、肿瘤直径（P ＜ 0.01）、分 化程度（P ＜ 0.01）、血管侵犯（P ＜ 0.01）和 TNM 分期（P ＜ 0.01）密切相关，差异具有统计学意义，而与患 者的年龄、性别、肝硬化、血清 AFP 水平、血清 NLR 值、肿瘤位置和肿瘤数量无关（P ＞ 0.05）。106 例 肝癌肝移植患者的组织中，复发组与未复发组相比，GHET1 表达明显升高（P ＜ 0.001）；高表达组与低表 达组相比，累积复发率明显升高（P ＜ 0.05），累积生存率明显下降（P ＜ 0.001），差异具有统计学意义。结论 GHET1 过表达与临床病理资料和不良预后相关，提示 GHET1 可能参与肝癌的发生和发展过程，可以作为 肝癌肝移植患者疾病预后标志物和临床治疗靶标。